New year, new opportunities: M&A life sciences trends has been saved
Perspectives
New year, new opportunities: M&A life sciences trends
Explore our 2024 life sciences M&A predictions
Life sciences M&A was a bright spot across the wider dealmaking world in 2023. Will this positive trend continue over the next 12 months? We think so. We’re making five bold 2024 life sciences M&A predictions, which include another strong year for pharma M&A and a positive turn for the MedTech market. Find out what else we expect this year.
Life sciences M&A: Looking back at 2023
Life sciences M&A dealmaking in 2023 was brighter than many expected, eclipsing the $135 billion figure from 2022, with $163 billion worth of deals announced through the end of October. The primary driver of strength in 2023 was the pharmaceutical segment, where 2023 M&A activity exceeded the same period in 2022 by 35%.
Based on these key life sciences trends, Deloitte sees momentum continuing into 2024.
2024 annual life sciences M&A predictions
Another positive year ahead
2023 will not go down as a banner year for life sciences M&A, but overall, deal value and transaction activity were resilient in spite of several macro headwinds that curtailed M&A activity in other sectors. With MedTech potentially rebounding, we think the life sciences M&A backdrop for 2024 looks favorable if not slightly more positive than it did heading into 2023.
Let’s talk about what these trends mean for you
Chris Caruso
Global Life Sciences & Healthcare Financial Advisory Leader
Recommendations
Four ways ESG is reshaping M&A
ESG considerations in M&A
Why a multidisciplinary approach is needed for diligence in software industry-based M&A
Acquiring software-based enterprises requires a unique M&A due diligence process. Deloitte has created a unique technical due diligence software platform for industry-specific merger and acquisition risk assessment.
